Back to results
US 2023/0144004 A1Published application
Delta-opioid receptor targeted agent for molecular imaging and immunotherapy of cancer
AssigneesH. Lee Moffitt Cancer Center and Research Institute, Inc., University of South Florida
InventorsMark L. McLaughlin, David L. Morse
Life of this patent
Estimating the term…
Abstract
The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target DOR and their use in the treatment of cancer.
Claims7
A compound comprising at least one delta-opioid receptor ligand conjugated to an anti-PD1 checkpoint inhibitor antibody, wherein the delta opioid receptor ligand is
- where R1 and R2 are independently selected from H and CH3.
2-8. (canceled)
Dependencies are inferred from the claim text.